A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity
Name
Sabatini_A diverse.pdf
Size
2.5 MB
Format
Adobe PDF
Checksum (MD5)
f5fcdea3aec196031188aaacfe2ea6c4
Author(s)
Grabiner, Brian C.
Nardi, Valentina
Birsoy, Kivanc
Possemato, Richard
Shen, Kuang
Sinha, Sumi
Jordan, Alexander
Beck, Andrew H.
Sabatini, David
Date Issued
March 2014
Journal
Cancer Discovery
Publisher
American Association for Cancer Research
Citation
Grabiner, B. C., V. Nardi, K. Birsoy, R. Possemato, K. Shen, S. Sinha, A. Jordan, A. H. Beck, and D. M. Sabatini. “A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity.” Cancer Discovery 4, no. 5 (March 14, 2014): 554–563.
Version
Author's final manuscript
Abstract
Genes encoding components of the PI3K–AKT–mTOR signaling axis are frequently mutated in cancer, but few mutations have been characterized in MTOR, the gene encoding the mTOR kinase. Using publicly available tumor genome sequencing data, we generated a comprehensive catalog of mTOR pathway mutations in cancer, identifying 33 MTOR mutations that confer pathway hyperactivation. The mutations cluster in six distinct regions in the C-terminal half of mTOR and occur in multiple cancer types, with one cluster particularly prominent in kidney cancer. The activating mutations do not affect mTOR complex assembly, but a subset reduces binding to the mTOR inhibitor DEPTOR. mTOR complex 1 (mTORC1) signaling in cells expressing various activating mutations remains sensitive to pharmacologic mTOR inhibition, but is partially resistant to nutrient deprivation. Finally, cancer cell lines with hyperactivating MTOR mutations display heightened sensitivity to rapamycin both in culture and in vivo xenografts, suggesting that such mutations confer mTOR pathway dependency.
Significance: We report that a diverse set of cancer-associated MTOR mutations confer increased mTORC1/2 pathway activity and that cells harboring these mutations are highly sensitive to rapamycin in culture and in vivo. These findings are clinically relevant as the MTOR mutations characterized herein may serve as biomarkers for predicting tumor responses to mTOR inhibitors.
MIT Department
Massachusetts Institute of Technology. Department of Biology
Whitehead Institute for Biomedical Research
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1158/2159-8290.cd-13-0929
